Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 03, 2021 / 05:20PM GMT
Release Date Price: €20.4 (-3.77%)
Kenneth Charles Cacciatore
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Thanks, everyone, for joining us. Thanks for Jack for being here and Stacy and Georgi with me today virtually, looking forward to seeing everyone next year live in Boston. But been a good substitute to be able to get everyone at least on the screens together.

Jack thanks, it's been a long time that we've known each other, been working with each other and seeing the evolution of the company from no commercial assets to really done a fantastic job with the original assets that you have.

And now you added WorldMeds and real exciting to talk about today 812. I thought it would be helpful to folks, clearly, I know your background, but maybe some that don't -- as it relates to the genesis of Supernus vis-Ã -vis some of the background you have in ADHD. I always find it helpful to rehear it, maybe it would be good for other folks to understand a little bit of the background before we set up a discussion on 812. So with that kind of open-ended comment, I'll throw it to you to just talk about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot